As tool compounds to study cardiac ischemia, the endogenous δ-opioid receptors (δOR) agonist Leu 5 -enkephalin and the more metabolically stable synthetic peptide [D-Ala 2 , D-Leu 5 ]enkephalin are frequently employed. However, both peptides have similar pharmacological profiles that restrict detailed investigation of the cellular mechanism of the δOR's protective role during ischemic events. Thus, a need remains for δOR peptides with improved selectivity and unique signaling properties for investigating the specific roles for δOR signaling in cardiac ischemia. To this end, we explored substitution at the Phe 4 position of Leu 5 -enkephalin for its ability to modulate receptor function and selectivity. Peptides were assessed for their affinity to bind to δORs and µ-opioid receptors (µORs) and potency to inhibit cAMP signaling and to recruit β-arrestin 2. Additionally, peptide stability was measured in rat plasma. Substitution of the meta-position of Phe 4 of Leu 5 -enkephalin provided high-affinity ligands with varying levels of selectivity and bias at both the δOR and µOR and improved peptide stability, while substitution with picoline derivatives produced lower-affinity ligands with G protein biases at both receptors. Overall, these favorable substitutions at the meta-position of Phe 4 may be combined with other modifications to Leu 5 -enkephalin to deliver improved agonists with finely tuned potency, selectivity, bias and drug-like properties.
Introduction
Leu 5 -enkephalin (Tyr 1 -Gly 2 -Gly 3 -Phe 4 -Leu 5 , Figure 1) is an endogenous opioid peptide produced in vertebrate species including rodents, primates and humans [1] [2] [3] [4] that results from the metabolism of proenkephalin or dynorphin [5] . Pharmacologically, Leu 5 -enkephalin agonizes the δ opioid receptor (δOR) with moderate selectivity over the µ opioid receptor (µOR), but does not significantly interact with the κ opioid receptor [6] . As a neurotransmitter in pain circuits, Leu 5enkephalin possesses antinociceptive properties [7] , whereas peripherally, the peptide demonstrates cardiovascular effects [8] . Over the last two decades, improved pharmacological characterization of opioid pathways has revealed that activation of an opioid receptor can trigger two distinct pathways, β-arrestin-dependent or β-arrestin-independent (i.e. G protein-mediated) and that these pathways differentially modulate antinociception and side effect profiles [9] .
Despite the increasing number of studies that implicate δOR mediated β-arrestin recruitment with various (patho)physiological effects, such as tolerance [10] , alcohol intake [11, 12] and δOR agonist-induced seizures [10] , the role of β-arrestin recruitment towards δOR-induced cardioprotection remains unclear.
From a translational perspective, peptide-based probes provide an ideal tool for studying the cardioprotective effects of the δOR, given their low brain penetration. While numerous enkephalin-like peptides have been synthesized that interact with excellent potency and selectivity for δORs and µORs [13] , a majority of studies [14] investigating δOR involvement in ischemia have utilized the synthetic peptide D-Ala 2 ,D-Leu 5 -enkephalin (DADLE, Figure   1 ) [15, 16] , because DADLE possesses improved proteolytic stability and improved selectivity for δORs over µORs relative to Leu 5 -enkephalin [6, 17] . However, DADLE's discovery in 1977 [18] , predated identification of β-arrestin as a modulator of opioid signaling [14, [19] [20] [21] , With the use of contemporary cellular assays it is now apparent that DADLE pharmacologically signals similarly to Leu 5 -enkephalin, though it recruits β-arrestin 2 (arrestin 3) slightly more efficaciously. Given the similarities between DADLE and Leu 5 -enkephalin, it is unclear to what degree β-arrestin recruitment contributes to or detracts from these peptides' in vivo cardioprotective efficacy, and new analogs with distinct pharmacolgocial profiles are necessary to probe these contributions.
To better investigate the role of δOR-mediated β-arrestin signaling in ischemic protection, the development of δOR selective agonists that have either low, intermediate or high β-arrestin is desired; however, reports of δOR selective peptide-based biased ligands remain limited.
Recently, the naturally occurring peptides rubiscolin-5 and -6 ( Figure 1) were classified as G protein-biased (β-arrestin 2 efficacy = 15% and 20%, respectively; δOR bias factor = 2.0) δOR selective peptides, albeit with only micromolar potencies [22] . While a number of synthetic peptides display nanomolar potencies at δORs, such as aza-β-homoleucine-enkephalin (β-arrestin 2 efficacy = 64%; δOR bias factor = 5.2) [23] and Dmt-Tic analogs [24] , these peptides all recruit β-arrestin 2 far more efficaciously than the rubiscolins (UFP-512: cAMP potency 0.4 nM, βarrestin 2 potency = 20 nM, efficacy = 60%) [23] [24] [25] . Additionally, these latter biased compounds, including aza-β-homoleucine-enkephalin and Dmt-Tic-Gly-NH-Ph, have at best 10fold selectivity for δORs over µORs and actually super-recruit β-arrestin 2 at µOR [23, 24] , which is likely to cause adverse, undesired in vivo effects [26, 27] . As such, our goal was to identify novel and potent δOR peptide agonists with varying degrees of β-arrestin recruitment efficacy, and that importantly have improved δOR selectivity over µOR while limiting β-arrestin recruitment at µOR. A collection of previously published structure activity relationship studies on Leu 5enkephalin directed us to Phe 4 as a position that can modulate δOR and µOR potency and selectivity (Figure 2A) [28] . Specifically, ortho and para substitutions on Phe 4 can modulate binding affinity and selectivity between opioid receptors [28] , and halogenation of the paraposition of Leu 5 -enkephalin and endomorphin 1 in particular appears to enhance δOR affinity while reducing µOR affinity [28] . Corroborating research has further shown that halogenation of the para position of Phe 4 of [D-Pen 2 ,D-Pen 5 ]enkephalin (DPDPE) enhanced δOR selectivity, potency, peptide stability, central nervous system (CNS) distribution, and antinociceptive potency compared to unsubstituted DPDPE [29] [30] [31] . Thus, halogenation at Phe 4 may provide Leu 5 -enkephalin derivatives that can be used to study not only cardiac but also cerebral ischemia [32, 33] . We herein report structure-activity-relationship trends at the meta-position of Phe 4 of Leu 5 -enkephalin ( Figure 2B) , demonstrating that substitution at this position variously regulates δOR and µOR affinity and G-protein activity, enables the fine-tuning of β-arrestin 2 recruitment to both δOR and µOR, and further increases the plasma stability of the derived peptides. Combined, these features provide a clear direction for designing the next-generation of Leu 5 -enkephalin analogs with well-defined biases and improved stabilities. 
Results and Discussion
Design Considerations: To probe the meta position of Phe 4 , we initially considered known structure-activity-relationship trends at the ortho and para positions of this residue. Considering that halogenated substituents at these positions perturbed binding affinity, δOR selectivity, and stability properties of the Leu 5 -enkephalin [28] , we initially hypothesized that meta-halogenated analogs might similarly perturb the parent scaffold ( Figure 3A, 1a-1d ). An additional set of analogs bearing electron-donating (1e-1f) and -withdrawing groups (1g-1i) would further probe interactions at this site, including the electronic character of the Phe 4 ring. Finally, pyridine analogs (1j-1l) would present H-bond accepting contacts about the ring, as well as provide analogs that present dipoles at similar vectors as to previously successful halogenated substituents.
Solid Phase Synthesis of Peptides: All peptides were synthesized using a rapid solid phase peptide synthesis protocol on an automated peptide synthesizer using an Fmoc protection strategy [34, 35] and N,N′-diisopropylcarbodiimide and oxyma as the coupling reagents ( Figure   3B ). Fmoc-Leu-Wang resin was utilized as a starting template for this synthetic protocol. All coupling steps and Fmoc-deprotection steps were carried out at 70 ºC under an atmosphere of N 2 .
Cleavage from the resin was performed using TFA/triisopropylsilane/H 2 O. Purification of the synthesized peptides was performed by reverse-phase high performance liquid chromatography (RP-HPLC), and analysis of purity was performed using ultra-performance liquid chromatography (UPLC). All desired peptides were obtained in ≥95% purity before submitting for pharmacological evaluation. Pharmacological Characterization: To characterize our substituted analogs, we assessed binding affinity by competition radioligand binding, G protein potency and efficacy using a cAMP GloSensor assay and β-arrestin 2 recruitment via PathHunter assays at both the δOR and µOR. Using Leu 5 -enkephalin as well as DAMGO (for µOR), as reference compounds, substitution of the meta position of Phe 4 (1a-1i) generally increased binding affinity for the δOR ( Table 1 , K i = 0.023-0.93 nM; Leu 5 -enkephalin = 1.26 nM) and µOR (K i = 0.059-0.98 nM;
Leu 5 -enkephalin = 1.7 nM). The improved binding affinity correlated with improved functional activation of the G protein pathway at both the δOR and µOR, while providing near-full agonist activity at the δOR (Table S1 , 92-100% efficacy) relative to Leu 5 -enkephalin , and mostly nearfull agonist activities at the µOR (Table S1 , 85-105% efficacy; Leu 5 -enkephalin = 100% efficacy vs. DAMGO). At the δOR, meta-substituted analogs recruited β-arrestin 2 with a range of potencies ( Table   2 , EC 50 : 0.56-49 nM; Leu 5 -enkephalin = 8.9 nM) with near-full efficacies ( Table 2 , 91-130%;
Leu-enkephalin = 100%), and likewise at the µOR, analogs recruited β-arrestin 2 with a broad range of potencies ( Table 2 , EC 50 : 36-589 nM; Leu-enkephalin = 977 nM) and efficacies ( Table   2 , 60-96% relative to DAMGO; Leu-enkephalin = 60%; Figure 4 ). Interestingly, DADLE recruited β-arrestin 2 more efficaciously than Leu 5 -enkephalin at both δOR (126%) and µOR (99%). Picoline analogs 1j-l, generally showed reduced affinity at both receptors ( Table 1 , δOR K i = 6.2-33 nM; µOR K i = 9-158 nM), which further correlated with decreased G protein activation of the receptors ( Within these overall trends, specific analogs show unique profiles. Meta-chlorination,bromination, or -iodination (1b-d) produced high-affinity analogs of Leu 5 -enkephalin that superrecruited β-arrestin 2 and that drastically increased functional selectivity ( Table 3) . These increases in affinity at δOR might derive from halogen bonding interactions that have been previously explored at the ortho and para positions of Phe 4 that improve affinity up to 6-fold [28] .
Though the improved δOR affinity at the meta position is significantly greater than the perturbations imparted by Cl, Br, or I at the ortho position (up to 6-to 17-fold, based on δOR construct) [28] . Notably, the meta-chlorinated and -brominated analogs (1b, and 1c) are 500-900fold more potent in cAMP assays at δOR than at µOR, despite exhibiting little differences in binding affinity at δOR relative to µOR ( Table 1) . Interestingly, the meta-Cl analog (1b) had stronger bias towards G protein-signaling at δOR ( Table 3 , bias factor 1.6), but towards βarrestin 2 recruitment at µOR relative to Leu 5 -enkephalin ( Table 3 , bias factor 0.004) as well as DAMGO ( Table 3 , bias factor 0.3), which provides a unique pharmacological profile for future uses. In contrast, meta-F and -CN and -NO 2 -substitutions (1a,h,i) improved δOR functional selectivity ( Table 3) , but lost β-arrestin 2 potency at δOR relative to Leu 5 -enkephalin.
Additionally, meta-OMe and -NO 2 substitution (1f, 1i) provided both potent and biased analogs, with G protein coupling activities comparable to Leu 5 -enkephalin ( Table 2 , IC 50 = 0.14-0.47 nM vs. 1.02 nM), but with improved bias factors relative to Leu 5 -enkephalin at both δOR ( Table 3, bias factor 6.9-7.5) and µOR ( Table 3 , bias factor 8.4-11.1). Of these two analogs, the -NO 2substituted analog 1i exhibited higher δOR functional G protein selectivity ( Table 3 , 104-fold δOR selectivity) relative to the -OMe analog 1f ( Table 3 , 58-fold δOR selectivity). Though pyridyl-substituted analogs (1j-l) showed poor potency and efficacy for the δOR and µOR relative to Leu 5 -enkephalin (Table 2) , the 3-and 4-pyridyl analogs (1k-l) showed strong bias at µOR ( Table 3 , bias factor 17-331), when compared to the full agonist DAMGO. However, if instead of DAMGO, Leu 5 -enkephalin was used as the reference compound, most analogs, with the exception of 1k and 1l lost G protein bias ( Table 3 , bias factor <1), because the analogs generally were more potent and efficacious than Leu 5 -enkephalin in recruiting β-arrestin 2 at µOR ( Table 2) , with the exception of 1k ( Table 2 , 36% recruitment efficacy). Given that exogenous Leu 5 -enkephalin analogs in vivo would compete with endogenous Leu 5 -enkephalin and not DAMGO, our results highlight the limitations of interpreting bias factors (particularly using an unnatural compound, such as DAMGO, as a reference) and the associated risk of using bias factor as a major driver of lead optimization. Compared to DADLE, the Leu 5 -enkephalin analogs 1b and 1c displayed a similar signaling bias profile, but were more potent and selective for δOR, and thus may provide a better tool compound to target δORs for the treatment of cardiac ischemia. However, compounds 1b and 1c
are also more potent than DADLE at recruiting β-arrestin 2 to µOR, resulting in a lower bias factor (Figure 4) . In contrast, analog 1i has a favorable pharmacology relative to DADLE, with similar selectivity as 1c, but improved G-protein bias at δOR and µOR relative to DADLE.
Given the potential adverse effects associated with strong µOR-mediated β-arrestin 2 recruitment, analog 1k is potentially useful, as it exhibited weak β-arrestin 2 recruitment (36% efficacy) and concomitant strong bias factor for G-protein signaling. However, cAMP potency for 1k at δOR was more than one log unit weaker than DADLE, and thus it may be necessary further optimize the ligand by increasing δOR potency in the cAMP assay, while retaining the low µOR β-arrestin 2 recruitment efficacy (Figure 4 ). 
Stability:
The stability of all compounds to Sprague Dawley rat plasma was assessed to study the influence of the meta-and picoline/pyridine-substitutions at Phe 4 relative to Leu 5 -enkephalin ( Table 4 ). For this parent compound, the predominant known routes of metabolism and clearance occur through cleavage of Tyr 1 -Gly 2 by aminopeptidase N [36, 37] , and of Gly 3 -Phe 4 by angiotensin converting enzyme [38] , and combined, the plasma metabolism occurs with a half-life (t 1/2 ) of < 10 min. In general, meta substituted Phe 4 analogs exhibited improved plasma stability compared with Leu 5 -enkephalin with half-lives typically >20 min. The 3-fluoro derivative (1a) was the most stable analog with a half-life of 82.3 min. From UPLC-mass spectrometry analysis of degradation fragments, meta-substitution did not greatly impede the proteolysis at the Tyr 1 -Gly 2 site, but instead slowed digestion at the Gly 3 -Phe 4 site (Table 4) .
Thus, the improved stability of our Phe 4 -substituted analogs presumably derived from perturbation/deceleration of angiotensin-converting enzyme activity. Picoline peptides also displayed improved stability though interestingly, UPLC-mass spectrometry analysis indicated that degradation of all pyridyl-substituted analogs (1j-l) predominantly occurred through Tyr 1 -Gly 2 as opposed to meta-substituted analogs 1a-i that degraded through cleavage of Gly 3 -Phe 4 .
Table 4. Rat Plasma Stability of Leu 5 -enkephalin and Its Analogs

Compound
Half-life (min) 95% CI Degradation products (first appearance)
Leu 5 -enkephalin 9.4 6.3− 4.5 Gly-Gly-Phe-Leu (5 min) Phe-Leu (10 min Peptides were synthesized using an Aapptec Focus XC automated peptide synthesizer coupled with a heating system using a solid phase peptide synthesis protocol using Fmoc chemistry.
Preparative RP-HPLC was performed using an appropriate column and solvent system 
Synthesis of Peptides.
Peptides were synthesized using a solid phase peptide synthesis protocol using an Aapptec Focus XC automated peptide synthesizer coupled with a heating system using the Fmoc chemistry and Wang resin as solid support [34] . To prepare the resin for synthesis, a Cell culture and biased signaling assays. cAMP inhibition and β-arrestin 2 recruitment assays were performed as previously described [12] . In brief, for cAMP inhibition assays HEK 293 (Life Technologies, Grand Island, NY, USA) cells were transiently transfected in a 1:3 ratio with (Table S2 ) as previously described [12] . Subsequently, bias factors were calculated using Leu 5 -enkephalin as reference compound for δOR and using either DAMGO or Leu 5 -enkephalin as reference compound for µOR, respectively. Leu 5 -enkephalin and DAMGO were more potent in the cAMP (G protein) assay than in the β-Arrestin 2 recruitment assay, and thus were not unbiased, but rather G protein-biased to begin with. A bias factor >1 meant that the agonist was more G protein-biased than the reference compound; A bias factor <1 meant that the agonist was less G protein-biased than the reference compound.
Data and Statistical analysis. All data are presented as means ± standard error of the mean, and analysis was performed using GraphPad Prism 8 software (GraphPad Software, La Jolla, CA).
For in vitro assays, nonlinear regression was conducted to determine pIC 50 (cAMP) or pEC 50 (βarrestin 2 recruitment). Technical replicates were used to ensure the reliability of single values, specifically each data point for binding and β-arrestin recruitment was run in duplicate, and for the cAMP assay in triplicate. The averages of each independent run were counted as a single experiment and combined to provide a composite curve in favor of providing a 'representative' curve. In each experimental run, a positive control/reference compound was utilized to allow the data to be normalized and to calculate the log bias value.
Assessment of Plasma Stability. Sprague Dawley rat plasma containing K 2ethylenediaminetetraacetic acid (Innovative Research, MI, USA) was transferred into 300 µL aliquots and stored at -20 ºC until use. The plasma stabilities of Leu 5 -enkephalin and its synthesized analogs were determined in plasma diluted to 50% with saline (isotonic sodium chloride solution; 0.9% w/v) [40] . An aliquot of the resulting solution (25 μL) was incubated at 37 °C for 15 min before the addition of a solution of a Leu 5 -enkephalin analog (25 μL of a 100 μM isotonic NaCl solution; 0.9% w/v). After adding analog, an aliquot of the mixture was removed at each indicated time point (0, 5, 10, 15, 20, 30, 60, 120, 240 min) and immediately quenched with 100 μL of a methanol solution containing 20 μM Fmoc-Leu-OH as an internal standard. The resulting peptide solutions were centrifuged at 13,000 rpm for 15 min at 4 °C on tubes equipped with 2000 MW filtrate tubes (Sartorius, USA). Then, the filtrate was transferred into vials and a 5 μL sample of the resulting solution was analyzed on an UPLC system coupled with a QDa detector. For quantitative determination, area-under-the-curve for the peaks corresponding to the UV chromatogram was measured for both the Leu 5 -enkephalin analog and the internal standard. Determination of half-life (t 1/2 ) was carried out by using the GraphPad Prism one-phase decay method.
Supplementary Material
Supplementary materials are available online. Specifically, for compounds 1a-l:
Additional pharmacological characterization, stability data, NMR spectra and characterization data for peptides, UPLC traces for determining purity. 
